https://pittplusme.org/study/1442
Hidradenitis Suppurativa Study
We're sorry. This study is closed and no longer recruiting participants.
STUDY BASICS
Have you been diagnosed with Hidradenitis Suppurativa (HS)? If so, you may be eligible for a study to help researchers compare two different doses of the study drug, guselkumab (TREMFYA®), to see if it is effective and safe for treating HS. Guselkumab is approved to treat patients with moderate-to-severe plaque psoriasis. Study involves 15 in-person visits over a year. Compensation is provided.
IRB: 6385C-010
- A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa
AGE:
18 and up
DURATION:
1 year
VISITS:
15 visits
LOCATION:
Falk Medical Building - Oakland
COMPENSATION:
$55.00 per visit
SHARE STUDY
MEET THE RESEARCHER
Laura Ferris
Laura Korb Ferris, MD, PhD, is Professor of Dermatology at the University of Pittsburgh School of Medicine, and is also the Director of Clinical Trials for the Department of Dermatology. Dr. Ferris earned her doctorate in immunology from Johns Hopkins University and her medical degree from the University of Maryland.